AXL Inhibition Specialist BerGenBio's $24m Private Placement To Fund Pipeline, Trials
BerGenBio CEO says the Norwegian biotech aims, either alone or in partnership, to develop and commercialize its lead asset through to marketing approval in a variety of cancers.
You may also be interested in...
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Pandemic Perspectives: Acacia CEO Says Pre-Existing Commercial Relationships, End-User Backing Key To Product Launches
Despite sector lockdowns there, Acacia has just launched two hospital-based products in the US. Its CEO Mike Bolinder tells Scrip how it defied the pandemic to get its drugs to their users.
The CEO of Oculis tells Scrip the Swiss biotech can become a major ophthalmic player and that its lead asset could become the first topical drug treatment for retinal edema.